FDA Publishes Draft Guidance Concerning Sameness in ANDAs
The latest guidance from FDA discusses recommendations on demonstrating sameness between the active ingredient in a proposed generic drug product and its reference listed drug.
FDA published a draft guidance concerning sameness evaluations in abbreviated new drug applications (ANDAs) on Nov. 8, 2022. The guidance discusses recommendations on demonstrating sameness between the active ingredient in a proposed generic drug product and its reference listed drug.
In addition to general recommendations on demonstrating sameness, the guidance provides additional considerations for products like synthetic peptides and complex mixtures. The guidance also provides non-binding examples of active ingredient characterization in the drug product.
The draft guidance can be viewed in full here. FDA is soliciting comments on the guidance through Jan. 8, 2022.
Source: FDA
Hesperos, Psilera Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
